WASHINGTON, June 10 (Reuters) - Cheaper versions of expensive biotechnology drugs would save patients money but are unlikely to drive down prices as much as generic competition has cut the cost of antibiotics and other, simpler medicines, a Federal Trade Commission report said on Wednesday.
